A 5-year Observational Follow-up Study to Describe Treatment Patterns in Real World of HCV Patients in China.

• HCV RNA level [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • HCV RNA level when on HCV treatments
  
  

• Subjects ratio of cirrhosis, HCC and death [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Evaluation of HCV disease progression (cirrhosis, HCC, death) over time regardless treatment options
  
  
• Viral genotypes of subjects [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  Evaluation of impacts of risk factors, such as viral genotypes on disease progression overtime
  
  
• Host genotypes of subjects [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  Evaluation of impacts of risk factors, such as host genotypes on disease progression overtime
  
  
• Diabetes status of subjects [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  Evaluation of impacts of risk factors, such as diabetes status on disease progression overtime
  
  

A sample of 600 Han ethnic Chinese male or female who are ≥ 18 years old enrolled and completed in the study of AI452-009 (i.e., CCgenos cross sectional phase, ClinicalTrials.gov Identifier: NCT01293279). In the AI452-009 study, all patients had a recent confirmation of anti-HCV-antibody positive and HCV RNA positive but antiviral treatment naive from 28 university affiliated hospital in China. The primary objective of this study (AI452-018, CCgenos follow up phase, ClinicalTrials.gov Identifier: NCT01293279) is to observe and describe long-term patient management and treatment patterns with associated outcomes of patients who previously enrolled in Protocol AI452009 (i.e., the CCgenos cross sectional phase, ClinicalTrials.gov Identifier: NCT01293279) and had their genotype characterized at diagnosis of HCV infection in a real world clinical practice in China.